Subject:
- Active Substance: Olopatadin / mometason
- Name: Ryaltris®
- Therapeutic area: Allergic Rhinitis
- Pharmaceutical company: Berlin-Chemie AG
Time table:
- Start: 01.12.2022
- Publication of assessment: 01.03.2023
- End of public hearing: 22.03.2023
- Final decision by G-BA: beginning of 2023
Comparative therapy:
- Intranasal glucocorticoid (INCS) in combination with intranasal antihistamine (INAH)